Expert Interviews

Dr Narjust Florez discusses the KRYSTAL-1 trial, focusing on the effectiveness and side effects of adagrasib in treating patients with NSCLC and KRASG12C mutations, and noting their impact on progression-free and overall survival.

Ibrutinib plus venetoclax appears to be effective across the overall chronic lymphocytic leukemia population in the CAPTIVATE study, although progression-free survival is shorter for those with TP53 mutations.

A review of adagrasib in the KRYSTAL-1 trial in patients with NSCLC.

Osimertinib monotherapy as the standard of treatment for frontline EGFR mutant advanced NSCLC will be replaced by combination therapies.

The panel closes by sharing final thoughts in the management of relapsed/refractory multiple myeloma, with a shared sense of optimism for advancements in treatment.

Mr. Fuentes felt it was important to understand the range of potential side effects to anticipate how his body would potentially react to treatment for RCC and determine his physical abilities and support needs, but was most focused on whether his first post-treatment scan showed tumor shrinkage.

Nurses play a key role in kidney cancer care by educating patients on medications, closely monitoring and managing side effects, coordinating care, providing emotional support, and serving as the first line of communication with patients about treatment concerns.

Key opinion leaders review the management of CAR-T therapy side effects in patients with relapsed/refractory multiple myeloma, including cytokine release syndrome and neurotoxicity, and emphasize the importance of early supervision and known toxicity timing.

EGFR-mutated stage IB-IIIA non-small cell lung carcinoma that has been removed and treated with adjuvant osimertinib.

A discussion on the Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients with ALK Positive Advanced NSCLC: Phase III CROWN Study

It is important to look at different assays beyond immunohistochemistry to better gather information and potentially predict the activity of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer, says Paolo Tarantino, MD.

The expert panel provides clinical insights on the role of CAR T-cell therapy and factors that influence treatment selection in the second line and beyond.

Multiple myeloma specialists outline frailty assessment practices and discuss how frailty informs treatment decisions.

The safety profile of idecabtagene vicleucel in relapsed/refractory multiple myeloma following the first 3 months of treatment appears to be comparable with standard therapies, says Rachid Baz, MD.

The panel reviews treatment strategies for HER2-positive metastatic colorectal cancer patients in various scenarios, including those with HER2 mutations, RAS mutations, and different levels of HER2 expression, emphasizing the importance of reprofiling and considering the duration of response before changing treatment approaches.

Experts explore the management of interstitial lung disease in patients with colorectal cancer receiving treatment with trastuzumab deruxtecan and the consideration of liquid biopsies to assess HER2 status and adapt treatment strategies.

Marwan G. Fakih, MD, and Atif Hussein, MD, MMM, FACP, conclude their discussion with advice for clinicians treating patients with metastatic colorectal cancer.

The panel discusses the safety profile of talquetamab for patients with relapsed/refractory multiple myeloma.

Colorectal cancer specialists discuss the effect of the SUNLIGHT trial data on the overall treatment and research landscapes.

Donna Catamero, ANP-BC, OCN, CCRC, reviews findings from the MonumenTAL-1 study and the panel provides its impressions of the results.